¼¼°è »ý¸í°úÇÐ ºÐ¼® ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 157¾ï ´Þ·¯·Î ÀÓ»ó½ÃÇè¿¡¼ ºÐ¼® ¼Ö·ç¼ÇÀÇ Ã¤¿ë Áõ°¡¿Í °³º°È ÀǾàǰ ¼ö¿ä¿¡ ÈûÀÔ¾î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ÀÓ»ó ¿¬±¸ÀÇ º¹ÀâÈ¿¡ ´ëÀÀÇϱ⠶§¹®¿¡ ÀÓ»ó½ÃÇè¿¡¼ ºÐ¼® ¼Ö·ç¼ÇÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ½Ç½Ã°£ Áö½ÄÀ» Á¦°øÇϰí, Å×½ºÆ® µðÀÚÀÎÀ» Á¤±³ÇÏ°Ô Çϰí ÀÇ»ç°áÁ¤À» °ÈÇÔÀ¸·Î½á º¸´Ù È¿À²ÀûÀÎ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Pharma IntelligenceÀÇ 2023³â Á¶»ç¿¡ µû¸£¸é °í±Þ ºÐ¼®À» »ç¿ëÇÏ´Â ÀÓ»ó½ÃÇè ÈÄ¿øÀÚÀÇ 65%´Â ½Å¼ÓÇÑ È¯ÀÚ ¸ðÁý ¹× º¸´Ù Á¤È®ÇÑ µ¥ÀÌÅÍ ºÐ¼®À» Æ÷ÇÔÇÑ ½ÃÇè È¿À²ÀÌ 25% Çâ»óµÇ¾ú½À´Ï´Ù.
±â¼ú Çõ½ÅÀº »ý¸í °úÇÐ ºÐ¼®ÀÇ È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº ¿¹Ãø ¸ðµ¨¸µ°ú µ¥ÀÌÅÍ ºÐ¼®À» Á¤±³ÇÏ°Ô Çϰí, ¾öû³ µ¥ÀÌÅͼ¼Æ®ÀÇ ¸é¹ÐÇÑ ºÐ¼®À» °¡´ÉÇÏ°Ô Çϰí, ÀǾàǰ °³¹ß ¹× °³ÀÎÈ Ä¡·á Àü·«¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÆÐÅÏÀ» ¹àÇôÁÝ´Ï´Ù.
2023³â ¸ÅÃâÀº 91¾ï ´Þ·¯·Î ¼ºñ½º ºÐ¾ß°¡ ½ÃÀåÀ» °ßÀÎÇß½À´Ï´Ù. »ý¸í°úÇÐ ±â¾÷Àº ¿¬±¸ ¼ö¿ä, ±ÔÁ¦ ±âÁØ ¹× µ¥ÀÌÅÍ º¹À⼺¿¡ ¸Â´Â ¸ÂÃãÇü ºÐ¼® ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù. ¼ºñ½º Á¦°ø¾÷ü´Â ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀ» ¼³°è, ±¸Çö, °ü¸®Çϰí ÃÖÀûÀÇ ¼º´ÉÀ» º¸ÀåÇϱâ À§ÇØ Áö¼ÓÀûÀÎ Áö¿ø, ¾÷µ¥ÀÌÆ® ¹× À¯Áöº¸¼ö¸¦ Á¦°øÇϸç ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.
2023³â¿¡´Â ¿µ¾÷¡¤¸¶ÄÉÆÃ Áö¿ø ºÐ¾ß°¡ 36¾ï ´Þ·¯·Î ÃÖ°í ¸ÅÃâÀ̾ú½À´Ï´Ù. »ý¸í°úÇÐ ±â¾÷Àº ½ÃÀå µ¿ÇâÀ» ÆÄ¾ÇÇÏ°í °í°´ ÇൿÀ» ÀÌÇØÇÏ¸ç ½ÃÀå °æÀï·ÂÀ» Æò°¡Çϱâ À§ÇØ ºÐ¼®¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. ¿µ¾÷ ¹× ¸¶ÄÉÆÃ ¾Ö³Î¸®Æ½½ºÀÇ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº Ÿ°Ù ¸¶ÄÉÆÃ Àü·«À» ¼¼¿ì°í ¿µ¾÷ Á¢±Ù ¹æ½ÄÀ» Á¤±³ÇÏ°Ô ¸¸µé°í »õ·Î¿î ½ÃÀå ±âȸ¸¦ ãÀ» ¼ö ÀÖ½À´Ï´Ù. °³ÀÎÈµÈ µ¥ÀÌÅÍ Áß½ÉÀÇ ¸¶ÄÉÆÃÀº °í°´ Âü¿©¸¦ °ÈÇϰí ÀüȯÀ²À» ³ôÀ̰í ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.
2023³â¿¡´Â ºÏ¹Ì°¡ 670¸¸ ´Þ·¯ÀÇ ¼öÀÍÀ¸·Î »ý¸í°úÇÐ ºÐ¼® ½ÃÀåÀ» µ¶Á¡ÇßÀ¸¸ç 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 7.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀÇ °í±Þ ÀÇ·á ÀÎÇÁ¶ó´Â ÃÖ÷´Ü ºÐ¼® ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í °Ç° °ü¸® Á¦°ø¾÷ü¿Í »ý¸í °úÇÐ ±â¾÷ÀÌ ´õ ³ªÀº ÀÇ»ç °áÁ¤°ú ȯÀÚ °á°ú¸¦ À§ÇØ µ¥ÀÌÅÍ ºÐ¼®À» Ȱ¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ºÏ¹Ì¿¡¼´Â ƯÈ÷ »ý¸í°øÇаú ÀǾàǰÀ» Áß½ÉÀ¸·Î ÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Ȱ¹ßÇØÁö±â ¶§¹®¿¡ Çõ½ÅÀ» ÃËÁøÇϰí ÀǾàǰ °³¹ßÀ» °£¼ÒÈÇÏ´Â ¾Ö³Î¸®Æ½½º Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
The Global Life Science Analytics Market was valued at USD 15.7 billion in 2023 and is projected to grow at a CAGR of 8.2% from 2024 to 2032, fueled by the rising adoption of analytical solutions in clinical trials and the demand for personalized medicines.
One key driver is the increasing use of analytical solutions in clinical trials, addressing the growing complexity of clinical research. These solutions provide real-time insights, refine trial designs, and enhance decision-making, leading to more efficient outcomes. For example, a 2023 study by Pharma Intelligence found that 65% of clinical trial sponsors using advanced analytics saw a 25% boost in trial efficiency, including quicker patient recruitment and more precise data analysis.
Technological innovations are enhancing the efficiency of life science analytics. AI and machine learning integration refines predictive modeling and data interpretation, allowing meticulous analysis of vast datasets and revealing patterns that influence drug development and personalized treatment strategies.
The overall life science analytics industry is classified based on component, type, application, deployment mode, end-use, and region.
The services segment led the market with a revenue of USD 9.1 billion in 2023. Life sciences companies seek bespoke analytics solutions tailored to their research demands, regulatory standards, and data intricacies. Service providers design, implement, and manage these solutions, offering continuous support, updates, and maintenance to ensure optimal performance, bolstering the segment's growth.
In 2023, the sales and marketing support segment topped the revenue charts with USD 3.6 billion. Life sciences firms rely on analytics to gauge market trends, understand customer behavior, and assess competitive dynamics. Insights from sales and marketing analytics empower companies to craft targeted marketing strategies, refine sales approaches, and spot emerging market opportunities. Personalized, data-driven marketing enhances customer engagement and boosts conversion rates, propelling the segment's growth.
In 2023, North America dominated the life science analytics market with a revenue of USD 6.7 million and is projected to grow at a CAGR of 7.7% from 2024 to 2032. The region's advanced healthcare infrastructure facilitates the adoption of cutting-edge analytics solutions, allowing healthcare providers and life sciences firms to harness data analytics for better decision-making and patient outcomes. North America's substantial investments in R&D, especially in biotechnology and pharmaceuticals, amplify the demand for analytics tools that foster innovation and streamline drug development.